Linked Life Data

18005850

Source:http://linkedlifedata.com/resource/pubmed/id/18005850

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2007-11-16
pubmed:abstractText
Stem cell transplantation (SCT) has emerged to be an appealing tool for repair medicine. In the treatment of ischemic heart diseases, SCT will be of great help because it is capable of replacing scar with new myocardial tissue. Among the many candidate cell lines for SCT, embryonic stem cells (ESCs) have their unique advantages. However, the controversy about the host immune attack and the transplanted ESCs or their derivatives transplanted into ischemic heart still existed. In this review, the immune properties of ESCs and ESC-derived cardiomyocytes and possible mechanisms were discussed; furthermore, the prevention strategies against potential immune responses were also identified.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0966-3274
pubmed:author
pubmed:issnType
Print
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
88-93
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Embryonic stem cell transplantation for the treatment of myocardial infarction: immune privilege or rejection.
pubmed:affiliation
Research Center for Cardiovascular Regenerative Medicine, the Ministry of Health and the Department of Surgery, Fu Wai Hospital, CAMS & PUMC, Beijing, 100037, China.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't